TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Immutep Ltd ( (AU:IMM) ).
Immutep Limited has released its corporate governance statement for the financial year ending 30 June 2025, which is available on their website. The statement, approved by the board, outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, highlighting its commitment to transparency and accountability in its operations. This disclosure is crucial for stakeholders as it ensures compliance with governance standards, potentially impacting the company’s reputation and investor confidence.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Limited operates in the biotechnology industry, focusing on the development of immunotherapy treatments. The company is primarily engaged in advancing its pipeline of products aimed at modulating the immune system to combat cancer and autoimmune diseases.
Average Trading Volume: 2,429,062
Technical Sentiment Signal: Buy
Current Market Cap: A$448.9M
For a thorough assessment of IMM stock, go to TipRanks’ Stock Analysis page.